BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cao GD, He XB, Sun Q, Chen S, Wan K, Xu X, Feng X, Li PP, Chen B, Xiong MM. The Oncolytic Virus in Cancer Diagnosis and Treatment.Front Oncol. 2020;10:1786. [PMID: 33014876 DOI: 10.3389/fonc.2020.01786] [Cited by in Crossref: 28] [Cited by in F6Publishing: 34] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Obozina AS, Komedchikova EN, Kolesnikova OA, Iureva AM, Kovalenko VL, Zavalko FA, Rozhnikova TV, Tereshina ED, Mochalova EN, Shipunova VO. Genetically Encoded Self-Assembling Protein Nanoparticles for the Targeted Delivery In Vitro and In Vivo. Pharmaceutics 2023;15. [PMID: 36678860 DOI: 10.3390/pharmaceutics15010231] [Reference Citation Analysis]
2 Jain S, Sheth RA. Modulating the tumor immune microenvironment with locoregional image-guided interventions. Front Immunol 2022;13:1057597. [PMID: 36685505 DOI: 10.3389/fimmu.2022.1057597] [Reference Citation Analysis]
3 Kaviarasan V, Ragunath B, Veerabathiran R. Oncolytic virus cancer therapeutic options and integration of artificial intelligence into virus cancer research. Oncogenic Viruses 2023. [DOI: 10.1016/b978-0-12-824156-1.00001-7] [Reference Citation Analysis]
4 Hassan ST, Mohamed AF, AbdelAllah NH, Zedan H. Evaluation of MMR live attenuated vaccine oncolytic potential using Ehrlich ascites carcinoma in a murine model. Med Oncol 2022;40:6. [PMID: 36308603 DOI: 10.1007/s12032-022-01866-x] [Reference Citation Analysis]
5 Thangavelu S, Ramanthan S, Velmurugan P, Dhandapani R. Virotherapy. Viral Infections and Antiviral Therapies 2023. [DOI: 10.1016/b978-0-323-91814-5.00030-1] [Reference Citation Analysis]
6 Dymova MA, Kichkailo AS, Kuligina EV, Richter VA. Aptamers Enhance Oncolytic Viruses' Antitumor Efficacy. Pharmaceutics 2022;15. [PMID: 36678780 DOI: 10.3390/pharmaceutics15010151] [Reference Citation Analysis]
7 Liu Y, Xu C, Xing C, Chen M. Influencing factors and prediction methods of radiotherapy and chemotherapy in patients with lung cancer based on logistic regression analysis. Sci Rep 2022;12:21094. [PMID: 36473918 DOI: 10.1038/s41598-022-25592-6] [Reference Citation Analysis]
8 Hu H, Xia Q, Hu J, Wang S. Oncolytic Viruses for the Treatment of Bladder Cancer: Advances, Challenges, and Prospects. J Clin Med 2022;11. [PMID: 36498574 DOI: 10.3390/jcm11236997] [Reference Citation Analysis]
9 Wang J, Du L, Chen X. Oncolytic virus: A catalyst for the treatment of gastric cancer. Front Oncol 2022;12:1017692. [PMID: 36505792 DOI: 10.3389/fonc.2022.1017692] [Reference Citation Analysis]
10 Fang X, Yan Q, Liu S, Guan XY. Cancer Stem Cells in Hepatocellular Carcinoma: Intrinsic and Extrinsic Molecular Mechanisms in Stemness Regulation. Int J Mol Sci 2022;23:12327. [PMID: 36293184 DOI: 10.3390/ijms232012327] [Reference Citation Analysis]
11 Lee YH, Tsai KW, Lu KC, Shih LJ, Hu WC. Cancer as a Dysfunctional Immune Disorder: Pro-Tumor TH1-like Immune Response and Anti-Tumor THαβ Immune Response Based on the Complete Updated Framework of Host Immunological Pathways. Biomedicines 2022;10:2497. [PMID: 36289759 DOI: 10.3390/biomedicines10102497] [Reference Citation Analysis]
12 Alirezaie B, Foroughi A, Mohammadi A. Isolation and Characterization of a Discrete Genetically Homogeneous Viral Subpopulation of Mumps Virus RS-12 Strain with Superior Oncolytic Potency Compared to Its Progenitor Virus. Int J Cancer Manag 2022;15. [DOI: 10.5812/ijcm-122781] [Reference Citation Analysis]
13 Hooda-nehra A, L. Smith T, I. Ferrer A, I. Staquicini F, Arap W, Pasqualini R, Rameshwar P. Targeted Regulation and Cellular Imaging of Tumor-Associated Macrophages in Triple-Negative Breast Cancer: From New Mechanistic Insights to Candidate Translational Applications. Macrophages celebrating 140 years of discovery [Working Title] 2022. [DOI: 10.5772/intechopen.105654] [Reference Citation Analysis]
14 Hoang DM, Pham PT, Bach TQ, Ngo ATL, Nguyen QT, Phan TTK, Nguyen GH, Le PTT, Hoang VT, Forsyth NR, Heke M, Nguyen LT. Stem cell-based therapy for human diseases. Signal Transduct Target Ther 2022;7:272. [PMID: 35933430 DOI: 10.1038/s41392-022-01134-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Garmaroudi GA, Karimi F, Naeini LG, Kokabian P, Givtaj N, Rehman MU. Therapeutic Efficacy of Oncolytic Viruses in Fighting Cancer: Recent Advances and Perspective. Oxidative Medicine and Cellular Longevity 2022;2022:1-14. [DOI: 10.1155/2022/3142306] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Liu T, Zhao N, Shi M, Shen Y, Mao C, Zhou X. Phage‐Derived Oncolytic Viruses with 3C from Seneca Valley Virus for Targeted Therapy of Cervical Cancer. Advanced Therapeutics. [DOI: 10.1002/adtp.202200059] [Reference Citation Analysis]
17 Goubran H, Stakiw J, Seghatchian J, Ragab G, Burnouf T. SARS-CoV-2 and cancer: The intriguing and informative cross-talk. Transfus Apher Sci 2022;:103488. [PMID: 35753906 DOI: 10.1016/j.transci.2022.103488] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Nadukkandy AS, Ganjoo E, Singh A, Dinesh Kumar L. Tracing New Landscapes in the Arena of Nanoparticle-Based Cancer Immunotherapy. Front Nanotechnol 2022;4:911063. [DOI: 10.3389/fnano.2022.911063] [Reference Citation Analysis]
19 Keshavarz M, Mohammad Miri S, Behboudi E, Arjeini Y, Dianat-Moghadam H, Ghaemi A. Oncolytic virus delivery modulated immune responses toward cancer therapy: Challenges and perspectives. Int Immunopharmacol 2022;108:108882. [PMID: 35623296 DOI: 10.1016/j.intimp.2022.108882] [Reference Citation Analysis]
20 Vogelbaum MA, Li G, Heimberger AB, Lang FF, Fueyo J, Gomez-Manzano C, Sanai N. A Window of Opportunity to Overcome Therapeutic Failure in Neuro-Oncology. Am Soc Clin Oncol Educ Book 2022;42:1-8. [PMID: 35580289 DOI: 10.1200/EDBK_349175] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Liu W, Wang X, Feng X, Yu J, Liu X, Jia X, Zhang H, Wu H, Wang C, Wu J, Yu B, Yu X. Oncolytic adenovirus-mediated intratumoral expression of TRAIL and CD40L enhances immunotherapy by modulating the tumor microenvironment in immunocompetent mouse models. Cancer Lett 2022;535:215661. [PMID: 35325845 DOI: 10.1016/j.canlet.2022.215661] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Orzetti S, Tommasi F, Bertola A, Bortolin G, Caccin E, Cecco S, Ferrarin E, Giacomin E, Baldo P. Genetic Therapy and Molecular Targeted Therapy in Oncology: Safety, Pharmacovigilance, and Perspectives for Research and Clinical Practice. Int J Mol Sci 2022;23:3012. [PMID: 35328435 DOI: 10.3390/ijms23063012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Schirrmacher V. Molecular Mechanisms of Anti-Neoplastic and Immune Stimulatory Properties of Oncolytic Newcastle Disease Virus. Biomedicines 2022;10:562. [DOI: 10.3390/biomedicines10030562] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Soleimanjahi H, Heydarabadi FH. Reovirus and Rotaviruses. Encyclopedia of Infection and Immunity 2022. [DOI: 10.1016/b978-0-12-818731-9.00050-1] [Reference Citation Analysis]
25 Malliou A, Kyritsis AP, Alexiou GA. Immunotherapeutic Strategies for Glioma Treatment. Interdisciplinary Cancer Research 2022. [DOI: 10.1007/16833_2022_71] [Reference Citation Analysis]
26 Bilgiç B, Dokuzeylül B, Or ME. Oncolytic virotherapy and the current approaches in veterinary medicine. Ger J Vet Res 2022;2:17-27. [DOI: 10.51585/gjvr.2022.2.0032] [Reference Citation Analysis]
27 Rashed WM. Immunotherapy for Pediatric Cancer. Handbook of Cancer and Immunology 2022. [DOI: 10.1007/978-3-030-80962-1_246-1] [Reference Citation Analysis]
28 Liu JKH, Irvine AF, Jones RL, Samson A. Immunotherapies for hepatocellular carcinoma. Cancer Med 2021. [PMID: 34953051 DOI: 10.1002/cam4.4468] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
29 Zhang C, Peng L, Ji J, Jiao W. [Research Progress of Circular RNAs in Tumor Immunotherapy]. Zhongguo Fei Ai Za Zhi 2021;24:698-704. [PMID: 34628781 DOI: 10.3779/j.issn.1009-3419.2021.101.31] [Reference Citation Analysis]
30 Sun H, Li J, Hu W, Yan Y, Guo Z, Zhang Z, Chen Y, Yao X, Teng L, Wang X, Li L, Chai D, Zheng J, Wang G. Co-immunizing with HMGB1 enhances anti-tumor immunity of B7H3 vaccine in renal carcinoma. Mol Immunol 2021;139:184-92. [PMID: 34560414 DOI: 10.1016/j.molimm.2021.09.002] [Reference Citation Analysis]
31 Santos Apolonio J, Lima de Souza Gonçalves V, Cordeiro Santos ML, Silva Luz M, Silva Souza JV, Rocha Pinheiro SL, de Souza WR, Sande Loureiro M, de Melo FF. Oncolytic virus therapy in cancer: A current review. World J Virol 2021; 10(5): 229-255 [PMID: 34631474 DOI: 10.5501/wjv.v10.i5.229] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
32 Ma J, Zhang C, Shi G, Yue D, Shu Y, Hu S, Qi Z, Chen Y, Zhang B, Zhang Y, Huang A, Su C, Zhang Y, Deng H, Cheng P. High-dose VitC plus oncolytic adenoviruses enhance immunogenic tumor cell death and reprogram tumor immune microenvironment. Mol Ther 2021:S1525-0016(21)00470-6. [PMID: 34547462 DOI: 10.1016/j.ymthe.2021.09.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
33 Cheng G, Dong H, Yang C, Liu Y, Wu Y, Zhu L, Tong X, Wang S. A review on the advances and challenges of immunotherapy for head and neck cancer. Cancer Cell Int 2021;21:406. [PMID: 34332576 DOI: 10.1186/s12935-021-02024-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
34 Zhao Y, Liu Z, Li L, Wu J, Zhang H, Zhang H, Lei T, Xu B. Oncolytic Adenovirus: Prospects for Cancer Immunotherapy. Front Microbiol 2021;12:707290. [PMID: 34367111 DOI: 10.3389/fmicb.2021.707290] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
35 Addou S, Sarkozy C, Lazarovici J, Champiat S, Stamatoullas A, Jardin F, Ribrag V, Marabelle A, Michot JM. Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation? Hum Vaccin Immunother 2021;:1-9. [PMID: 34101538 DOI: 10.1080/21645515.2021.1924521] [Reference Citation Analysis]
36 An Y, Wang X, Wu X, Chen L, Yang Y, Lin X, Wang N, Duan J, Long S, Zhao X. Oncolytic reovirus induces ovarian cancer cell apoptosis in a TLR3-dependent manner. Virus Res 2021;301:198440. [PMID: 33940002 DOI: 10.1016/j.virusres.2021.198440] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
37 Zhang Z, Lu M, Qin Y, Gao W, Tao L, Su W, Zhong J. Neoantigen: A New Breakthrough in Tumor Immunotherapy. Front Immunol 2021;12:672356. [PMID: 33936118 DOI: 10.3389/fimmu.2021.672356] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 14.5] [Reference Citation Analysis]
38 Heidbuechel JPW, Engeland CE. Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies. J Hematol Oncol 2021;14:63. [PMID: 33863363 DOI: 10.1186/s13045-021-01075-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 9.5] [Reference Citation Analysis]
39 Badie F, Ghandali M, Tabatabaei SA, Safari M, Khorshidi A, Shayestehpour M, Mahjoubin-Tehran M, Morshedi K, Jalili A, Tajiknia V, Hamblin MR, Mirzaei H. Use of Salmonella Bacteria in Cancer Therapy: Direct, Drug Delivery and Combination Approaches. Front Oncol 2021;11:624759. [PMID: 33738260 DOI: 10.3389/fonc.2021.624759] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
40 Sasso E, D'Alise AM, Zambrano N, Scarselli E, Folgori A, Nicosia A. New viral vectors for infectious diseases and cancer. Semin Immunol 2020;50:101430. [PMID: 33262065 DOI: 10.1016/j.smim.2020.101430] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 8.7] [Reference Citation Analysis]